All In Biotech

Drug Trial Radar · NCT06366451

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

May 22, 2024

Primary completion

Mar 25, 2026

Study completion Mar 25, 2026

Sponsor

Lead sponsor
Presage BiosciencesIndustry
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients presenting with Head and Neck Squamous Cell Carcinoma (HNSCC) with a surface accessible lesion, who are scheduled for tumor and/or regional node dissection as part of their standard treatment. PD effects due to injected investigational agents, either as single agents or as AZD9592 drug combinations with the evaluated biologics, will be compared to those elicited by pembrolizumab alone, which will also be injected in microdose quantities via the CIVO device.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • RilvegostomigBiological

    Intratumoral microdose injection by the CIVO device.

  • VolrustomigBiological

    Intratumoral microdose injection by the CIVO device.

  • SabestomigBiological

    Intratumoral microdose injection by the CIVO device.

  • AZD9592Biological

    Intratumoral microdose injection by the CIVO device.

  • PembrolizumabBiological

    Intratumoral microdose injection by the CIVO device.

  • AZD9592 + RilvegostomigCombination product

    Intratumoral microdose injection by the CIVO device.

  • AZD9592 + VolrustomigCombination product

    Intratumoral microdose injection by the CIVO device.

  • AZD9592 + SabestomigCombination product

    Intratumoral microdose injection by the CIVO device.

  • AZD9592 + PembrolizumabCombination product

    Intratumoral microdose injection by the CIVO device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of signature scores using Gene Set Variability Analysis within regions injected with microdoses of rilvegostomig, volrustomig, sabestomig, AZD9592, or pembrolizumab as single agents or as AZD9592 drug combinations with the evaluated biologicsTime frame: 1 to 3 days after microdose injection

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis

    Sacramento, California

  • Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Medical Center

    Charleston, South Carolina

  • Medical University of South Carolina

    Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.